Embecta Q2 revenue up 3.6% to $287.2M; raises FY2024 guidance above prior range

Embecta Corp.

2024-Q2 EPS reported $0.85 revenue$564,500,000

Revenue of $287.2M (+3.6% reported, +4.5% constant currency); U.S. +0.8%, International +6.8%.
Adjusted EPS of $0.67 vs $0.75 prior year; adjusted operating margin of 26.1% vs 30.6%.
Raised FY2024 guidance: revenue $1,111-1,116M (prev. $1,094-1,116M), adj. EPS $2.20-2.30 (prev. $1.95-2.15).
FDA continues review of insulin patch pump 510(k); ERP implementation covers ~85% of revenue.
Declared quarterly dividend of $0.15/share, payable June 14, 2024 to holders of record May 28, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Embecta Corp. reported three and six month periods ended March 31, 2024 results: revenue $287.2 million, net income $28.9 million, EPS $0.50. Guidance raised.

Period: three and six month periods ended March 31, 2024
Revenue: $287.2 million
Net income: $28.9 million
EPS: $0.50
Guidance: raised
Result: reported results

Exact text from the filing

half of the year, we are raising and tightening our fiscal 2024 outlook for our key financial metrics." Second Quarter Fiscal Year 2024 Financial Highlights : • Revenues of $287.2 million, up 3.6% on a reported basis; up 4.5% on a constant currency basis ◦ U.S. revenues increased 0.8% on both a reported and constant currency basis ◦ International revenues

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Embecta Corp. filing history →

Source: SEC EDGAR

accession 0001872789-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.